13:45 - 13:55 Opening ceremony

• N Kröger (EBMT President)
• J Gribben (EHA President)

14:00 - 15:00 Session 1: Clinical indications I

Chairs: N Kröger (Germany) & J Gribben (United Kingdom)

• CAR-T cells in adult ALL
  A Nagler (Israel)
• CAR T-cell Therapy for MM: Current Concepts – Perspective for the Future
  H Einsele (Germany)
• Factors associated with outcomes of CD19 CAR-T cell therapy
  C Turtle (United States)
• Q&A

15:00 - 15:30 Break

15:30 - 16:30 Session 2: Clinical indications II

Chairs: C Roddie (United Kingdom) & C Bonini (Italy)

• Lymphomas – DLBCL
  P Corradini (Italy)
• CAR-T in AML
  Gerhard Ehninger (Germany)
• Mantle Cell Lymphoma
  R Houot (France)
• Q&A

16:30 - 17:00 Break

17:00 - 17:45 Keynote lecture

Chairs: H Einsele (Germany) & C Chabannon (France)

• Title to be announced
  S Riddell (United States)
• Q&A

17:50 - 18:20 Best abstracts & Flash talks

• Universal chimeric antigen receptor (CAR)-engineered T cells from induced pluripotent stem cells
  A Nianias (The Netherlands)
• Title to be announced
  N Ho (Germany)
• Antibiotic-induced Microbiome Injury in CAR T-cell Patients correlates with Toxicity and Outcome
  V Blumenberg (Germany)
• ARI-0001 CART19 cells in relapsed B-ALL with Isolated Extramedullary Disease
  V Ortiz-Maldonado (Spain)
• CD19 hypermethylation as an escape to CART-19
  M Smida (Czech Republic)

18:25 - 19:10 Satellite symposium by Janssen: A new chapter in the treatment of patients with relapsed / refractory multiple myeloma

Chair: MV Mateos (Spain)

• Clinical advances with CAR-Ts and bispecifics in relapsed/refractory multiple myeloma
  A Cohen (United States)
• A look into the future: possibilities for advanced therapy medicinal products in the management of patients with multiple myeloma
  MV Mateos (Spain)
• Panel discussion and Q&A

09:00 - 09:45 Keynote lecture

Chairs: M Subklewe (Germany) & I Yakoub-Agha (France)

• Progression of CAR T trials in China
  JX Wang (China)
• Q&A

09:45 - 10:00 Break

PARALLEL SESSIONS - Physicians program

10:00 - 11:00 Session 3: Optimizing CAR T-cell therapy

Chairs: H Einsele (Germany) & A Nagler (Israel)

• Mechanisms behind CAR T cells
  M Maus (United States)
• Virus-free CAR-T at the bench and in the clinic
  M Hudecek (Germany)
• Tumor glycosylation: impact on CAR T-cell efficacy
  M Casucci (Italy)

11:00 - 11:15 Break

11:15 - 12:15 Session 4: Pediatrics in CAR-T

Chairs: A Künkele (Germany) & T Feuchtinger (Germany)

• The challenges of CAR T cell therapy for pediatric B-ALL
  S Ghorashian (United Kingdom)
• Beyond CD19 CAR T cells for B-ALL
  R Gardner (United States)
• From hematological malignancies to solid tumor treatment: The journey of CAR T therapy in the pediatric setting
  C Quintarelli (Italy)
• Q&A

12:20 - 12:50 Best abstracts & Flash talks

• Title to be announced
  M Wermke (Germany)
• CAR-Treg Therapy for Systemic Lupus Erythematous
  M Doglio (Italy)
• JULIET: 40-month clinical update and biomarker analysis
  P Corradini (Italy)
• Sleeping Beauty engineered CAR T cells for B-ALL
  CF Magnani (Italy)
• Title to be announced
  MAV Marzolini (United Kingdom)
• Title to be announced
  K Rejeski (Germany)

13:00 - 13:45 Satellite Symposium by Kite and Gilead: Reaching new landmarks in survival with CAR T-cell therapy

Chair: M Dreyling (Germany)

• CAR T-cell therapy in NHL: The story so far (4-year landmark)
  A Sureda (Spain)
• Reshaping the treatment paradigm in R/R mantle cell lymphoma: Perspective on CAR T
  M Dreyling (Germany)
• Patient case discussion
  L Ysebaert (France)
• Q&A

13:45 - 15:00 Break

• 14:15 - 14:45 Meet the Expert: M Mause (United States)
  No registration required. Limited space available. 

15:00 - 15:45 Satellite Symposium by Bristol Myers Squibb: Practical aspects of CAR T-cell therapy

Chair: U Jaeger (Austria)

• CAR T-cell therapy in the daily care of patients with B-cell malignancies
  P Borchmann (Germany)
• Implementation of CAR T-cell therapy in MM: practical and patient-related aspects
  MV Mateos (Spain)
• Q&A

15:50 - 16:50 Session 5: Interactive pros/cons: future application of CAR T-cells

Chair: H Einsele (Germany) & F Ciceri (Italy)

• BITE vs CART: Pro BITE
  M Subklewe (Germany)
• BITE vs CART: Pro CART
  C Thieblemont (France)
• CAR vs BITEs in multiple myeloma
  S Anguille (Belgium)
• Q&A

16:55 - 17:55 Session 6: CAR effector cells (non T-Cells)

Chairs: C Roddie (United Kingdom) & M Hudecek (Germany)

• Adoptive cell therapy with tumor-redirected iNKT cells
  P Dellabona (Italy)
• CARs NK
  U Köhl (Germany)
• Allogeneic CAR Ts
  R Benjamin (United Kingdom)
• Q&A

17:55 - 18:15 Break

18:15 - 19:00 Keynote lecture

Chairs: C Chabannon (France) & J Gribben (United Kingdom)

• Epigenetic landscaping of CAR T cells - Early insights
  M Sadelain (United States)
• Q&A

19:05 - 19:50 IMI Project Workshop: How to rapidly move new CAR-Ts forward from bench to bedside? Key questions and answers!

Chairs: M Hudecek (Germany) & S Wagers (BE)

• Interactive panel discussion hosted by the imSAVAR and T2EVOLVE IMI projects
  I Marchiq (France)
  U Koehl (Germany)
  J Moggs (Switzerland)
  S Riddell (United States)

PARALLEL SESSIONS - Nurses program

10:00 - 10:05 Introduction & welcome

• E Aerts (Switzerland)

10:05 - 11:05 Session 1

Chair: E Aerts (Switzerland)

• Establishing a multiprofessional CAR T Cell Communication Board
  M Spalt (Austria)
• Immune Effector Cells in Solid Tumors
  J Ritchie (United Kingdom)
• Where are we now and where are we going with pediatric CAR-T?
  F Ceppi (Switzerland)
• Q&A

11:05 - 11:15 Break

11:15 - 12:35 Session 2

Chair: J Murray (United Kingdom)

• Post Infusion blood tests, what are they all for?
  A Patel (United Kingdom)
• Does it work in other hematological diseases?
  R Benjamin (United Kingdom)
• What centre requirements are needed for JACIE?
  R Wosley (United Kingdom)
• GoCART
  S Terwel (The Netherlands)
• Q&A

12:35 - 15:45 Break

15:45 - 16:35 Session 3

Chair: M Ni Chonghaile (Ireland)

• Spotlight on the Lymphoma Patient Experience
  L Warwick (Canada)
• Q&A
• Group Discussion – Ethics of CAR-T
  • R Ting (United Kingdom)
  • L Warwick (Canada)
  • E Aerts (Switzerland)
  • M Spalt (Austria)

16:35 - 17:00 Break

17:00 - 18:00 Session 4

Chair: M Kenyon (United Kingdom)          

• Basic nursing care, a training program
  R Clout (United Kingdom)
• Case study
  R Ellard (United Kingdom)
• Survivorship Considerations after CAR T-Cell Therapy
  N Crisp (Canada)
• Q&A

18:00 - 18:10 Closing remarks

• M Kenyon (United Kingdom)
  

PARALLEL SESSIONS – Physicians program

09:30 - 10:30 Session 7: Side effects - Recognition and treatment including novel insights into pathophysiology

Chairs: M Casucci (Italy) & M Subklewe (Germany)

• Complications – cytopenias
  I Yakoub-Agha (France)
• CRS, ICANS and the steroids to prevent it
  M Topp (Germany)
• Infections in patients receiving immunotherapies such as CAR-T cells
  J Hill (United States)
• Q&A

09:30 - 10:30 Session 8: CAR T regulatory issues + reimbursements (in country and across borders)

Chairs: M Hudecek (Germany) & J Kuball (The Netherlands)

• Academic delivery through a national service
  A Urbano-Ispizua (Spain)
• CAR T access: Importance of reimbursement and manufacturing networks
  E Ostuni (Switzerland)
• Involving patients to solve the hurdles across the HTA process
  S Scowcroft (United Kingdom)
• Q&A

09:30 - 10:30 Session 9: Data Management: Real world data / LTFU / data collection

Chairs: M Mohty (France) & N Bolaños (Spain)

• Results of treatment with tisacel and axicel in real world conditions; report from the CIBMTR / CIDR
  M Pasquini (United States)
• Defining conditions for shared access to data collected in a global repository for EU CAR-T Cells treated patients
  S Terwel (The Netherlands)
• CAR-T cells: the experience of patients and carers
  G Bouguet (France)
• Q&A

10:30 - 11:00 Break

11:00 - 12:00 Session 10: Academic production

Chair: S Mielke (Sweden)

• Overcoming Cell Manufacturing Challenges in the Academic setting
  I Riviere (United States)
• Why regulatory and commercial aspects should be improved for the successful ACT academic clinical trials
  M Juan (Spain)
• Targeting SLAMF7 in Multiple Myeloma
  H Bönig (Germany)
• Q&A

11:00 - 12:00 Session 11: Clinical challenges in CAR-T

Chair: C Roddie (United Kingdom) & M Topp (Germany)

• Inclusion criteria
  C Thieblemont (France)
• Infectious complications in patients treated with CART
  M Angel Perales (United States)
• Factors Associated with Outcomes of Repeat CD19-targeted CAR T cell infusions for Refractory B cell Malignancies
  J Gauthier (United States)
• Q&A

11:00 - 12:00 Session 12: EU grants and projects

Chair: C Chomienne (France)

• EN-ACTI2NG: from TCRs to CARs and back
  HM van Santen (Spain), A Menon (Spain), T Wachsmann (The Netherlands), L Velas (Austria)
• CARAMBA & EURE-CART H2020 projects
  M Hudecek (Germany)
• imSAVAR & T2EVOLVE IMI projects
  U Köhl (Germany)
• Myeloma Patients Europe (MPE) in this H2020
  A Plate (Germany)
• Q&A

12:00 - 12:30 Break

12:30 - 13:15 Keynote lecture

Chairs: I Yakoub-Agha (France) & H Einsele (Germany)

• Updates with Engineered T Cells
  C June (United States)
• Q&A

13:20 - 13:35 Closing remarks

Meeting chairs:

• C Chabannon (France)
• H Einsele (Germany)

Association presidents

• N Kroeger (Germany) – EBMT President
• J Gribben (United Kingdom) – EHA President